You Position: Home > Paper
OBSERVATION OF CLINICAL CURATIVE EFFECT FOR ACUTE LEUKEMIA USING MITOXANTRONE AND OTHER CHEMOTHERAPY AGENTS
( views:455, downloads:4 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1009-9921.2001.06.006
- Key Word:
- 米托蒽醌;急性白血病;疗效
Abstract： 目的:观察米托蒽醌(MTZ)治疗初治、复发急性白血病(AL)的临床疗效和毒副作用.探索以MTZ为主要药物作为一线治疗药物的可行性.方法:急性髓细胞白血病(AML)诱导治疗采用MTZ和阿糖胞苷(Ara-C).急性淋巴细胞白血病(ALL)诱导治疗采用长春新碱(VCR)、MTZ、异环磷酰胺(IFO)和强的松(Pred),条件允许时加用左旋门冬酰胺酶(L-ASP).结果:37例患者中29例取得完全缓解(CR),CR率78.4%.对20例AML患者进行了随访,治疗多于6疗程以上的10例患者,有8例持续CR(CCR),中位缓解期15.5月.结论:米托蒽醌联合用药治疗急性白血病有较好的疗效,其毒副作用可以耐受.该方案可以作为一线方案用于AL的诱导治疗.
- [1]F, Brito-Babapulle,D, Catovsky,A C, Newland,etc.Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone.[J].1987,14(2 Suppl 1).
- [2]张之南.血液病诊断及疗效标准[M].1998.
- [3]Volker Heinemann,David Murray,Ronald Walters,etc.Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine[J].1988,22(3).
- [4]S, Amadori,G, Meloni,M C, Petti,etc.Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia.[J].1989,3.
- [5]Norwood T,Rankin C,Karanes C,etc.A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.[J].2000,24(3).